Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

被引：0
|
作者：
Edoardo Caronna
Victor José Gallardo
Alicia Alpuente
Marta Torres-Ferrus
Patricia Pozo-Rosich
机构：
[1] Universitat Autònoma de Barcelona,Neurology Department, Hospital Universitari Vall d’Hebron, Department of Medicine
[2] Universitat Autònoma de Barcelona,Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Medicine
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Migraine; Medication overuse; CGRP; Monoclonal antibodies; Erenumab; Galcanezumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
    Caronna, Edoardo
    Jose Gallardo, Victor
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01)
  • [2] Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
    Iannone, Luigi Francesco
    De Cesaris, Francesco
    Ferrari, Anita
    Benemei, Silvia
    Fattori, Davide
    Chiarugi, Alberto
    CEPHALALGIA, 2022, 42 (13) : 1323 - 1330
  • [3] Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years
    Pons-Fuster, E.
    Lozano-Caballero, O.
    Martin-Balbuena, S.
    Lucas-Rodenas, C.
    Mancebo-Gonzalez, A.
    De Gorostiza-Frias, I.
    Gonzalez-Ponce, C. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1317 - 1326
  • [4] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Cohen, Fred
    Yuan, Hsiangkuo
    DePoy, E. M. G.
    Silberstein, Stephen D.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 922 - 930
  • [5] Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis
    Vikelis, Michail
    Rikos, Dimitrios
    Argyriou, Andreas A.
    Dermitzakis, Emmanouil V.
    Andreou, Anna P.
    Russo, Antonio
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2025, 25 (03) : 359 - 374
  • [6] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Fred Cohen
    Hsiangkuo Yuan
    E. M. G. DePoy
    Stephen D. Silberstein
    Neurotherapeutics, 2022, 19 : 922 - 930
  • [7] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Simona Guerzoni
    Flavia Lo Castro
    Daria Brovia
    Carlo Baraldi
    Luca Pani
    Neurological Sciences, 2024, 45 : 1661 - 1668
  • [8] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Guerzoni, Simona
    Castro, Flavia Lo
    Brovia, Daria
    Baraldi, Carlo
    Pani, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1661 - 1668
  • [9] Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
    Simona, Guerzoni
    Carlo, Baraldi
    Daria, Brovia
    Michela, Cainazzo Maria
    Flavia, Lo Castro
    Luca, Pani
    ACTA NEUROLOGICA BELGICA, 2023, 123 (03) : 1039 - 1047
  • [10] Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention
    Lovati, Carlo
    Bernasconi, Gianna
    Capogrosso, Chiara
    Molteni, Laura
    Giorgetti, Federica
    Dell'Osso, Bernardo
    Pantoni, Leonardo
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5765 - 5767
12345